4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide has been researched along with Body Weight in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Habu, S; Kusunoki, M; Miyata, T; Mori, Y; Morishita, M; Nakamura, A; Nakamura, T; Nakaya, Y; Sato, D; Tsutsumi, K; Yonemoto, T | 1 |
| Tsutsumi, K; Yang, B; Yin, W; Yuan, Z | 1 |
| Fukuzawa, Y; Hara, T; Ikeda, H; Inoue, Y; Ishikawa, T; Kato, K; Kurokawa, T; Kusunoki, M; Miyata, T; Nakamura, T; Nakaya, Y; Ogawa, H; Okabayashi, N; Otake, K; Sakakibara, F; Tsutsumi, K | 1 |
| Doi, M; Kano, S | 1 |
| Chiba, T; Inoue, Y; Miura, S; Sawamura, F; Tomita, I; Tomita, T; Tsutsumi, K; Uetsuka, R | 1 |
| Ohara, M; Ohsawa, N; Tsutsumi, K | 1 |
| Fukatsu, A; Hara, T; Kakumu, S; Kato, K; Kusunoki, M; Miyata, T; Nakamura, T; Nakaya, Y; Nakayama, K; Ohnaka, M; Okada, K; Sakamoto, S; Tsutsumi, K | 1 |
| Fukuzawa, Y; Hara, T; Kakumu, S; Kusunoki, M; Miyata, T; Nakamura, T; Nakaya, Y; Ogawa, H; Sakakibara, F; Suga, T; Tsutsumi, K | 2 |
9 other study(ies) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and Body Weight
| Article | Year |
|---|---|
Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.
Topics: Abdominal Fat; Adiponectin; Animals; Benzamides; Blood Glucose; Body Weight; Drug Combinations; Eating; Enzyme Activation; Hypoglycemic Agents; Insulin; Leptin; Lipids; Lipoprotein Lipase; Male; Organophosphorus Compounds; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2011 |
Effects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild diabetic rabbits.
Topics: Animals; Arteriosclerosis; Benzamides; Blood Glucose; Body Weight; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Experimental; Eating; Enzyme Activators; Hypolipidemic Agents; Lipoprotein Lipase; Male; Organophosphorus Compounds; Rabbits; Sucrose; Triglycerides | 2002 |
Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Benzamides; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet; Dietary Fats; Enzyme Activators; Fatty Liver; Lipids; Lipoprotein Lipase; Male; Organ Size; Organophosphorus Compounds; Rats; Rats, Wistar | 2004 |
NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.
Topics: Adipose Tissue, Brown; Animals; Benzamides; Blood Glucose; Body Weight; Carrier Proteins; Eating; Fatty Acid Transport Proteins; Fatty Acid-Binding Proteins; Female; Gene Expression; Hypolipidemic Agents; Insulin; Ion Channels; Leptin; Mitochondrial Proteins; Muscle, Skeletal; Myocardium; Obesity; Organophosphorus Compounds; Ovariectomy; Oxygen Consumption; Proton-Translocating ATPases; Random Allocation; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Uncoupling Protein 3 | 2006 |
Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits.
Topics: Animals; Aorta; Aortic Diseases; Arteriosclerosis; Benzamides; Body Weight; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Cholesterol, HDL; Diet, Atherogenic; Glycoproteins; Hypercholesterolemia; Lipids; Lipoprotein Lipase; Male; Organophosphorus Compounds; Rabbits; Triglycerides | 1997 |
Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator.
Topics: Adipose Tissue; Animals; Benzamides; Blood Glucose; Blood Proteins; Body Weight; Cachexia; Cholesterol; Eating; Enzyme Activation; Leydig Cell Tumor; Lipoprotein Lipase; Lipoproteins, HDL; Male; Organophosphorus Compounds; Rats; Rats, Inbred F344; Testicular Neoplasms; Time Factors; Triglycerides | 1998 |
A lipoprotein lipase activator, NO-1886, improves endothelium-dependent relaxation of rat aorta associated with aging.
Topics: Aging; Animals; Aorta; Arteriosclerosis; Benzamides; Blood Glucose; Body Weight; Endothelium, Vascular; Enzyme Activation; Insulin; Lipid Peroxides; Lipids; Lipoprotein Lipase; Male; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Vasodilation | 1998 |
Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the lipoprotein lipase activator NO-1886.
Topics: Animals; Benzamides; Blood Glucose; Body Weight; Cholesterol; Dietary Fats; Enzyme Activation; Glucose Clamp Technique; Glycogen; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipids; Lipoprotein Lipase; Liver; Male; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Triglycerides | 2002 |
A lipoprotein lipase activator, NO-1886 prevents impaired endothelium-dependent relaxation of aorta caused by exercise in aged rats.
Topics: Aging; Animals; Aorta; Benzamides; Body Weight; Eating; Endothelium, Vascular; Hypolipidemic Agents; Lipid Peroxidation; Lipids; Lipoprotein Lipase; Male; Organophosphorus Compounds; Physical Conditioning, Animal; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Vasodilation | 2002 |